Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Working Capital?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1995 - 2021 (27 years)

Working Capital is 
4.1B (1Y +11.4% )

ALXN Stock Price & Working Capital

Working Capital for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Working Capital

chevron_right 2021 4.2B +1911x
( +32.3% / year avg)
chevron_left 1995 2.2M
vertical_align_top Peak 4.2B +1911x
vertical_align_bottom Bottom 2.2M
arrow_drop_up # Up Years 20 20 of 27
years up.
arrow_drop_down # Down Years 7
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1995 , or +0.02x the rate relative to it's working capital over the same period.
  • If ALXN grows it's stock at the same rate as it's working capital (+32.3%/year) , it's stock price will grow +1,642% and hit $1786.11 over the next 10 years.
  • ALXN's stock price has gone up 0 of the 20 years (0%) it's working capital were also up.
5-Year Change 🚀
+138%$6.4BNet Revenue (Sales)
+181%$608.8MCost of Revenue (Sales)
+135%$5.8BGross Profit Margin
-1.58%3.62Gross Profit Margin Ratio
+78.1%$1.2BResearch and Development (R&D)
+109%$1.8BSelling, General, and Administrative (SG&A)
+91.1%$3.2BTotal Operating Expenses
+101%$3.8BCost & Expenses
+38.7%$110.8MInterest Expense/Income, Net
+51.0%$300.4MDepreciation & Amortization (D&A)
+191%$2.9BEBITDA
+22.2%1.81EBITDA Margin
+227%$2.6BOperating Income
+37.0%1.63Operating Margin
-25.4%-$114.8MTotal Other Income/Expenses
+323%$2.4BPretax Income (Earnings)
+77.5%1.48Pretax Income (Earnings) Margin
-83.0%$219.2MProvision For Income Taxes
-391.6%$2.1BNet Income (Earnings)
-222.1%1.35Net Profit Margin
-401.9%9.78Earnings Per Share (EPS)
-401.9%9.78Earnings Per Share (EPS) Diluted
-3.15%$876.4MShares Outstanding
-3.15%$876.4MShares Outstanding (Diluted)
+154%$11.9BCash and Cash Equivalents
-88.2%$139.6MShort Term Investments
+105%$12.0BCash And Short-Term Investments
+227%$3.1BInventory
+135%$23.3BTotal Current Assets
+136%$5.8BPP&E
+1.69%$20.4BGoodwill
-37.3%$12.0BIntangible Assets
-17.4%$32.4BGoodwill and Intangible Assets
+37.6%$72.4BTotal Assets
+152%$474.4MAccounts Payables
-18.6%$569.6MShort-term Debt
+6,334%$1.1BOther Current Liabilities
+111%$6.5BTotal Current Liabilities
-27.2%$9.7BLong-term Debt
+291%$6.5BDeferred Tax Liabilities Non-Current
+147%$2.4BOther Non-Current Liabilities
+16.8%$19.3BTotal Non-Current Liabilities
+31.7%$25.8BTotal Liabilities
+370%$21.0BRetained Earnings
-331.5%-$500.0MAccumulated Other Comprehensive Income Loss
+41.2%$46.6BTotal Shareholders Equity
+37.6%$72.4BTotal Liabilities & Stockholders Equity
-26.8%$10.2BTotal Debt
-117.2%-$1.6BNet Debt
-128.0%-$436.8MDeferred Income Tax
+67.5%$342.0MStock-Based Compensation (SBC)
-1,029.8%$1.9BChange in Working Capital
+144%$176.4MAccounts Receivables
+145%$16.8BOther Working Capital
-154.3%-$67.2MOther Non-Cash Items
+276%$3.4BNet Cash Provided by Operating Activities
+1.9%-$310.0MInvestments in PP&E
-97.1%-$22.4MPurchase of Investments
-96.5%$10.0MSales/Maturities of Investments
-58.7%-$322.4MNet Cash used for Investing Activities
-16.7%-$306.0MCommon Stock Repurchased
-98.9%-$4.8MOther Financing Activities
-60.1%-$295.2MNet Cash Used Provided by Financing Activities
-1,272.3%$80.0MEffect of Exchange Rate Changes on Cash
-544.5%$2.8BNet Change in Cash
+160%$12.1BCash at End of Period
+76.1%$9.3BCash at Beginning of Period
+276%$3.4BOperating Cash Flow
+1.9%-$310.0MCapital Expenditure (capex)
+418%$3.1BFree Cash Flow
  • ALXN Historical Working Capital Table
    in million
    Year Working Capital YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 4,208 7.8% - -
    4/1/2020 3,904 38.1% - -
    4/1/2019 2,826 37.5% - -
    4/1/2018 2,056 12.7% - -
    4/1/2017 1,824 11.0% - -
    4/1/2016 1,644 -17.1% - -
    4/1/2015 1,984 6.8% - -
    4/1/2014 1,858 40.7% - -
    4/1/2013 1,321 69.5% - -
    4/1/2012 779 50.0% - -
    4/1/2011 519 40.5% - -
    4/1/2010 369 80.2% - -
    4/1/2009 205 15.7% - -
    4/1/2008 177 1.4% - -
    4/1/2007 174 10.0% - -
    4/1/2006 159 -23.5% - -
    4/1/2005 207 -7.4% - -
    4/1/2004 224 -0.2% - -
    4/1/2003 224 -25.9% - -
    4/1/2002 303 -15.4% - -
    4/1/2001 358 146.6% - -
    4/1/2000 145 408.7% - -
    4/1/1999 28 -20.1% - -
    4/1/1998 35 72.8% - -
    4/1/1997 20 25.5% - -
    4/1/1996 16 650.0% - -
    4/1/1995 2 - - -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.
  • Working capital = Total Current Assets - Total Current Liabilities


    For more detailed definitions, please see Investopedia.
    Year Working Capital YoY % Change Stock Price YoY % Change (Stock Price) total current liabilities total current assets
    4/1/2021 4208300000.00 7.8% 6498.80 23332.00
    4/1/2020 3904250000.00 38.1% 4765.30 20382.30
    4/1/2019 2826200000.00 37.5% 4240.50 15545.30
    4/1/2018 2056025000.00 12.7% 3966.30 12190.40
    4/1/2017 1824798250.00 11.0% 3699.34 10998.53
    4/1/2016 1644580666.67 -17.1% 2640.43 9218.76
    4/1/2015 1984816250.00 6.8% 2723.21 10662.47
    4/1/2014 1858608000.00 40.7% 1899.49 9333.92
    4/1/2013 1321376500.00 69.5% 1354.27 6639.78
    4/1/2012 779687500.00 50.0% 1321.01 4439.76
    4/1/2011 519708000.00 40.5% 754.72 2833.55
    4/1/2010 369992500.00 80.2% 373.59 1853.56
    4/1/2009 205299000.00 15.7% 374.64 1195.84
    4/1/2008 177465500.00 1.4% 212.17 922.03
    4/1/2007 174948750.00 10.0% 107.58 807.38
    4/1/2006 159034500.00 -23.5% 91.13 727.27
    4/1/2005 207799750.00 -7.4% 213.14 1044.34
    4/1/2004 224306500.00 -0.2% 68.12 965.35
    4/1/2003 224659750.00 -25.9% 52.06 950.70
    4/1/2002 303087500.00 -15.4% 55.31 1267.66
    4/1/2001 358409250.00 146.6% 30.24 1463.88
    4/1/2000 145359000.00 408.7% 23.34 604.78
    4/1/1999 28575000.00 -20.1% 19.80 134.10
    4/1/1998 35775000.00 72.8% 8.30 151.40
    4/1/1997 20700000.00 25.5% 7.60 90.40
    4/1/1996 16500000.00 650.0% 5.87 71.87
    4/1/1995 2200000.00 6.80 15.60